Loading stock data…
PLX
$2.12-0.03 (-1.40%)
Market ClosedLast close May 1
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Protalix BioTherapeutics, Inc. in the Healthcare sector is trading at $2.12. The stock is currently 34% below its 52-week high of $3.19, remaining 1.0% above its 200-day moving average. Technical signals show neutral RSI of 34 and bearish MACD signal, explaining why PLX maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 34) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.12
Potential Upside
5%
Whystock Fair Value$2.23
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$11.00+418.9%
Range$10.00 – $12.00
Fundamentals
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Ele...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$177.26M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-13.69%
Volume
Today's trading volume
721,516
Recent News
April 2026 Penny Stocks With Promising Potential
The market has climbed 3.4% in the last 7 days and an impressive 30% over the past year, with earnings projected to grow annually by 16%. In light of these robust market conditions, identifying stocks with strong financials becomes crucial for investors looking to capitalize on growth opportunities. Although often considered a relic, penny stocks still hold potential when backed by solid fundamentals, offering a unique blend of value and growth that might not be found in larger companies.
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
Protalix BioTherapeutics Inc (PLX) reports significant EU approval, financial gains, and R&D progress amidst increased expenses and market challenges.
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) reported its 2025 financial results and outlined recent regulatory, clinical and commercial developments, including a new European approval for its Fabry disease therapy and updated guidance for 2026. "2025 was a year of meaningful progress...
Protalix: Q4 Earnings Snapshot
HACKENSACK, N.J. (AP) — Protalix BioTherapeutics Inc. PLX) on Wednesday reported a loss of $5.5 million in its fourth quarter. On a per-share basis, the Hackensack, New Jersey-based company said it had a loss of 7 cents.
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has approved a new dosing regimen for pegunigalsidase alfa for adults with Fabry disease who are stable on enzyme replacement therapy (ERT), triggering a $25 million regulatory milestone payment from...